IONS Q2 2023 Earnings — Ionis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IONSIonis Pharmaceuticals, Inc.

$13B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$188M+40.8% YoY

Gross Profit

$186M98.7% margin

Operating Income

-$90M-47.9% margin

Net Income

-$85M-45.3% margin

EPS (Diluted)

$-0.59

QoQ Revenue Growth

+44.3%

Cash Flow

Operating Cash Flow

-$97M

Free Cash Flow

-$110M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$3.0B

Total Liabilities

$2.5B

Stockholders' Equity

$428M

Cash & Equivalents

$425M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$188M	$134M	+40.8%
Gross Profit	$186M	$129M	+44.0%
Operating Income	-$90M	-$86M	-5.5%
Net Income	-$85M	-$105M	+18.9%

Revenue Segments

Research and Development Revenue

$111M29%

Collaborative Agreement Revenue

$91M24%

Commercial

$78M21%

SPINRAZA Royalties

$61M16%

Eplontersen Joint Development Revenue

$20M5%

Other Commercial

$17M4%